Health-care companies ticked up amid deal activity.

CymaBay Therapeutics shares rallied after the clinical-stage biopharmaceutical company agreed to be acquired by Gilead Sciences for $4.3 billion.

Obesity drug makers Novo Nordisk and Eli Lilly gave back some of their torrid 2024 gains.

Write to Rob Curran at

(END) Dow Jones Newswires

02-12-24 1841ET